SARS-CoV-2 Gamma Variant Pseudovirus Expressing Luciferase
* The price is valid only in USA. Please select country.
-
More Files
- More Functions
-
Specification
Product Description
SARS-CoV-2 Gamma Variant Pseudovirus Expressing Luciferase can be used to measure neutralizing antibody against SARS-CoV-2.
Materials Required But NOT Supplied
1. 293T-hACE2 cell
2. SARS-CoV-2 Monoclonal Antibody, Cat# MAB22854-M07, Abnova
3. ZymeFree™ Enzyme Free Cell Dissociation Reagent,
Cat# TCL028-100ML, HIMEDIA
4. DMEM culture medium containing 10% FBS (complete medium)
5. Luciferase Assay System, Cat# E1500, Promega
a. Luciferase Assay Substrate (lyophilized)
b. Luciferase Assay Buffer
c. Luciferase Cell Culture Lysis Reagent, 5X
6. TC-Treated 24 Well Plates, Cat# 3524, Corning
7. OptiPlate™-96, Cat# 6005290, PerkinElmerVariant
B.1.1.28.1, P.1
Suitable Sample
1. Immunized Serum
2. Infected Serum
3. Neutralizing Antibodies
4. Peptide Inhibitors or Proteins
5. Compounds Targeting Spike Induced Cell FusionSample Volume
10-50 uL (please check sample source)
Detection Method
Luciferase Activity
Technology
Regulatory Status
For research use only (RUO)
Storage Instruction
Store at -80°C
Aliquot to avoid repeated freezing and thawing. -
Applications
Neutralization
RBD-binding IgG responses in mouse sera collected 35 days and 42 days after immunization with 5 ug or 20 ug COVID-19 RBD SAM LNP no adjuvant (ppopV0) and 5 ug or 20 ug COVID-19 RBD SAM plus adjuvant (ppopV1).Neutralization
SARS-CoV-2 gamma variant spike pseudovirus expressing luciferase is treated with humanized monoclonal antibody 7F7 and LALAPG 7F7, and then added into 293T-ACE cells.In vivo Neutralization
Hamsters received 2 doses of humanized monoclonal antibody 7F7 and then were infected with SARS-CoV-2 Gamma Variant Pseudovirus Expressing Luciferase (Cat # U0408).
- +1-909-264-1399
+1-909-992-0619
Toll Free : +1-877-853-6098 - +1-909-992-3401
- sales@abnova.com